

Sublingual immunization using supramolecular peptide-polymer conjugate tablets

Value proposition

Immunization with vaccines prevent illness, disability, and currently avert an estimated 2 to 3 million deaths every year. However, commonly-used vaccine technology platforms can be unpredictable, require a high manufacturing cost, and often need cold-chain storage. While these factors result in raised costs and less effective vaccinations, they also contribute to difficulties in access for developing nations. Peptide vaccines can answer many of these problems, but traditionally elicit a weak immune response. Additionally, common needle-based injections are costly, require skillful administration and waste management, and pose significant safety risks to both health workers and patients. The World Health Organization has estimated that over a million deaths occur each year due to needle cross-contamination. Needles are also a major psychological deterrent for many, with up to ten percent of patients admitting skipping flu shots due to fear of pain and injury during injection. There is a need for cheaper, more accessible vaccines that can be administered without needles.

Technology

The Collier lab at Duke has discovered that self-assembling peptide nanofibers can be rendered highly immunogenic by conjugating the assemblies to low molecular weight polyethylene glycol (PEG). These peptide-polymer assemblies can raise robust, antigen-specific responses against peptide epitopes that persist for at least a year when delivered sublingually. Additionally, they have demonstrated a dissolvable tablet capable of acting as a sublingual vaccine. This tablet is able to raise responses against the *M. tuberculosis* epitope ESAT6₅₁₋₇₀ and is additionally stable to heating for at least 1 week at 45 °C. A heat-stable, sublingually delivered peptide vaccine holds significant promise for lowering cost, controlling intervaccine variability, and improving vaccine accessibility.

Advantages

- Robust immune response in animal model demonstrated with peptide nanofibers
- Preparation is simple and cheap
- Needle-free vaccination will improve patient compliance and avoid the cost of needle disposal



Duke File (IDF)

T-005313

Inventor(s)

- Collier, Joel
- Kelly, Sean

Links

- [From the lab of Dr. Joel Collier](#)

College

Pratt School of Engineering

For more information please contact

Thomas, Dennis
919-681-7580
dennis.thomas@duke.edu

Publications

- [Active immunotherapy for TNF-mediated inflammation using self-assembled peptide nanofibers \(Biomaterials, 2017\)](#)
- [MyD88 in antigen-presenting cells is not required for CD4+ T-cell responses during peptide nanofiber vaccination \(Med Chem Comm, 2017\)](#)
- [PCT App US2018/042762](#)

Patents

Patent Number: 16/632,226

Title: SUPRAMOLECULAR PEPTIDE-POLYMER
CONJUGATES AND METHODS OF MAKING AND USING
SAME

Country: United States of America